418
Views
6
CrossRef citations to date
0
Altmetric
Letters to the Editor

A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukemia

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 1261-1264 | Received 29 Sep 2021, Accepted 18 Dec 2021, Published online: 31 Dec 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Articles from other publishers (5)

Andrea Ossato, Vera Damuzzo, Paolo Baldo, Daniele Mengato, Marco Chiumente & Andrea Messori. (2022) Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression‐free survival based on reconstructed individual patient data. Cancer Medicine 12:3, pages 2155-2165.
Crossref
Luca Cancanelli, Melania Rivano, Lorenzo Di Spazio, Marco Chiumente, Daniele Mengato & Andrea Messori. (2023) Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments. Hematology Reports 15:1, pages 57-65.
Crossref
Andrea Messori, Melania Rivano, Luca Cancanelli, Vera Damuzzo, Andrea Ossato, Marco Chiumente & Daniele Mengato. (2022) The “One-to-Many” Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma. Cureus.
Crossref
Sabrina Trippoli, Lorenzo Di Spazio, Marco Chiumente & Andrea Messori. (2022) Medical Therapy, Radiofrequency Ablation, or Cryoballoon Ablation as First-Line Treatment for Paroxysmal Atrial Fibrillation: Interpreting Efficacy Through the Shiny Method. Cureus.
Crossref
Lorenzo Di Spazio, Melania Rivano, Luca Cancanelli, Marco Chiumente, Daniele Mengato & Andrea Messori. (2022) The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors. Cureus.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.